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Abstract  
Introduction: ‘Store and forward’ teledermoscopy is a technology with potential advantages for 
melanoma screening. Any large-scale implementation of this technology is dependent on 
consumer acceptance. 
Aim: To investigate preferences for melanoma screening options compared to skin self-
examination in adults considered to be at increased risk of developing skin cancer. 
Methods: A discrete choice experiment (DCE) was completed by 35 consumers, all of whom 
had prior experience with the use of teledermoscopy, in Queensland, Australia. Participants 
made 12 choices between screening alternatives described by seven attributes including monetary 
cost. A mixed logit model was used to estimate the relative weights that consumers place on 
different aspects of screening, along with the marginal willingness to pay for teledermoscopy as 
opposed to screening at a clinic. 
Results: Overall, participants preferred screening/diagnosis by a health professional rather than 
skin self-examination. Key drivers of screening choice were for results to be reviewed by a 
dermatologist; a higher detection rate; fewer non-cancerous moles being removed in relation for 
every skin cancer detected; and less time spent away from usual activities. On average, 
participants were willing to pay AU$110 to have teledermoscopy with dermatologist review 
available to them as a screening option.  
Discussion & Conclusions: Consumers preferentially value aspects of care that are more 
feasible with a teledermoscopy screening model, as compared to other skin cancer screening and 
diagnosis options. This study adds to previous literature in the area which has relied on the use 
of consumer satisfaction scales to assess the acceptability of teledermoscopy.  
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
The state of Queensland in Australia has the highest rate of skin cancer in the world including 
the highest rate for melanoma mortality [1]. In 2011, there were 3,249 new cases of melanoma 
diagnosed in Queensland, which was the second leading form of cancer for both men and 
women [2]. In addition, around 133,000 cases of non-melanoma skin cancer are diagnosed in the 
state each year [3]. This presents a major challenge to health services in terms of the high 
number of cases, their differential diagnosis and often late presentation of tumours. The three 
main types of skin cancer detected are basal cell carcinoma (BCC), squamous cell carcinoma 
(SCC) and melanoma [4]. It is important to find all melanomas very early as recent results have 
shown that even those under 1mm thick may lead to death [5]. BCCs and SCCs also benefit 
from earlier detection, but due to their lower mortality rates, less crucially so.  Despite this there 
is currently no population-based screening program implemented in Queensland or Australia. 
People are advised to check their own skin (skin self-examination SSE) and present to a doctor 
urgently if any spots or moles change [6, 7]. Opportunistic screening is also performed by 
General Practitioners (GPs)(family doctors) and increasingly by skin cancer clinics, which are 
generally staffed by GP’s, some with additional training [8]. Dermatologists cannot be accessed 
directly by consumers in Australia, requiring a referral from a GP.  
Teledermoscopy is a technology that captures images of potential skin cancers using a hand-held 
dermatoscope. ‘Store and forward’ technology is used to upload and send the image for 
diagnosis [9, 10]. This technology is now available as a hardware addition to a mobile phone and 
consumers can submit good quality images for triage with minimal training [11]. Studies have 
found that results from teledermoscopy images, reviewed by an experienced teledermatologist, 
have high concordance with face-to-face diagnoses, as well as approximating 100% sensitivity 
and around 90% specificity to differentially diagnose melanoma and non-melanoma skin cancers 
[11-14]. Thus, teledermoscopy has the potential to assist with managing clinician workloads, 
increasing access to dermatologists and potentially avoiding unnecessary biopsies and other 
investigations which occur at a higher rate when performed by non-dermatologist and less 
experienced clinicians [15]. 
However consumer acceptance of this approach has yet to be established and is essential if broad 
implementation of this strategy is to be considered. Consumer preferences have predominantly 
been measured by ‘consumer satisfaction’ rating scales, with somewhat mixed results [16-22].  A 
review paper by Demiris et al. (2004) identified 14 studies related to consumer satisfaction and 
acceptance of teledermatology applications more broadly (including both the ‘store and forward’ 
technology as well as video conferencing). The authors concluded that the concept of 
satisfaction is multidimensional and should cover many underlying factors including convenience 
of the service; confidence in the result; and ease of communication with the clinician [18]. 
However, one of the main limitations with using satisfaction rating scales is that they are uni-
dimensional. 
A Discrete Choice Experiment (DCE) is a type of survey which elicits consumer preferences 
around service delivery in a number of different disciplines, including increasingly in health [23-
25]. DCEs are designed to simulate real-life consumer choice situations where more or less 
attractive characteristics of a product or service are traded relative to alternative options. In this 
way, the key average drivers of choice for a population can be determined and the potential value 
uptake of a new service estimated. In this study, we use DCE methodology to measure consumer 
preferences around the key characteristics of skin cancer screening options including 
teledermoscopy, in order to provide insights into their acceptability. In this study, we investigate 
the preferences for skin cancer screening options compared to skin self-examination in a group 
of people considered to be at increased risk of developing skin cancer. 
Methods 
A survey containing a DCE was developed and administered according to best practice 
guidelines [26].  Participants were asked to make 12 choices between two ‘generic’ health service 
options describing different combinations of screening services, either currently available or 
possible in the near future. Each screening alternative was described according to seven different 
screening attributes, the levels of which varied across the different alternatives in each choice set 
(Table 1).  
<< Table 1 about here >> 
These alternatives, and the different attribute levels over which they vary, were chosen based on 
the results of three previous surveys undertaken in the target group [11], as well as a literature 
review [14, 16-22, 27, 28] and included important screening outcome, financial and convenience 
considerations. In each choice set participants were also asked to compare these service options 
with two ‘opt out’ options – either skin self-examination (that is, performing a skin check on 
your own without the help of a health professional), or not to undertake any screening at all. 
The screening alternatives described by the attributes and levels in Table 1 were allocated into 
choice sets using a multinomial logit (mnl) d-efficient design, assuming no prior information 
about the likely magnitude or direction of coefficients (zero priors) [29, 30]. This optimised the 
likelihood of the design estimating statistically efficient preference parameters, despite the 
relatively small sample size and inclusion of opt out alternatives. To avoid unrealistic 
combinations of attributes and levels, a constraint was added to the design, since consumers 
cannot access a dermatologist for screening without a GP referral in Australia. Specifically, 
review by a GP was constrained to only appear with screening being performed at a skin cancer 
or GP clinic; whereas, screening by teledermoscopy could be reviewed by either a GP or a 
dermatologist. To reduce participant burden, two versions of the survey were created with 12 
unique choice questions contained in each version; participants were randomly allocated to each 
version. An example choice set is presented in Table 2.  
<< Table 2 about here >> 
The survey also collected information on socio-demographic characteristics; current and 
intended skin-screening practices; and the level of concern about developing skin cancer in the 
future. These questions had been validated before collection in previous questionnaires; however 
the choice questions had not been tested previously. 
 
 
Participant recruitment 
As prior experience of a good or service can be a strong influence on choice [31], it was decided 
to control for this by recruiting a sample who all had previous experience with teledermoscopy in 
a pilot teledermoscopy trial [11]. Participants from this trial who agreed to further contact were 
invited via email to complete the survey either online or on a paper-pencil copy we mailed to 
them. The inclusion criteria for the original study included: age 50-64 years; living in Queensland 
(residing in Brisbane or willing to travel); and considered to be at moderate or high risk for 
melanoma (they had to meet one of the following; fair eye, hair or skin type, previous skin 
excisions, or a personal or family history of melanoma). There were no exclusion criteria [11].  
Analysis of the choice data 
The DCE data were analysed using non-linear regression models, in which the attribute levels 
(independent variables) were used to explain participant screening choice (dependent variable).  
Here, we use a mixed-logit model (MMNL) which offers advantages to the more often used 
multinominal logit (MNL) [32, 33]. Details of the theoretical framework are provided in 
Appendix 1. A number of assumptions were made. Firstly, as no participants chose the “I would 
prefer not to undertake any screening” opt out option, this alternative was not included in the 
model. Instead, skin-self-examination was assumed to be the base alternative, the utility of which 
was assumed to be constant. All attributes except cost were effects coded to allow for non-linear 
relationships, especially for qualitative (unordered) variables. Costs were coded continuously. All 
attributes were initially modelled as random parameters. All distributions around random 
parameters were assumed to be normal and estimated using 1000 halton draws (this is a quasi-
random or “intelligent” method for simulating distributions often used in choice modelling [33]). 
If the standard deviations of the random parameters were found to be non-significant at the 10% 
level, the attribute was modelled as a non-random parameter. Similar to linear regression, a 
positive coefficient means that the attribute level of interest is preferred over those with a 
negative coefficient. 
Willingness to pay estimates 
Using the outputs from the model derived above, an indicative marginal willingness to pay 
(MWTP) was estimated for the hypothetical policy change from a situation where only skin-self-
assessment, GP screening and skin cancer clinic screening is available, to a situation where the 
option of teledermoscopy with review by a dermatologist is additionally available. This provides 
an estimate of the monetary value for the welfare gain (or loss) for consumers by having 
teledermoscopy available to them as an alternative. Following Lanscar [34] and Ryan [35], we use 
the method for compensating variation described by Small and Rosen [36] to estimate the 
welfare gain associated with different screening models. Compensating variation is a measure of 
how much money needs to be given or taken from a consumer after a price or quality change to 
leave them with their initial level of satisfaction (known as utility)[34]. This method accounts for 
both the relative importance of a given attribute level(s) as well as the probability of choosing an 
alternative which contains that particular attribute (Table 4). The Small and Rosen formula used 
is detailed in Appendix 2.  
 
Results 
 
Completed DCE surveys were returned by 35 participants (70% participation rate). There were 
no partial completions. A summary of the characteristics of the participants who completed the 
survey is presented in Table 3. 
 
<< Table 3 about here >> 
As can be seen from Table 3, participants were between 50 and 64 years, representing the age 
group with the highest incidence of melanoma (this was an inclusion criteria of the original trial).  
On average the participants had high levels of education and income and were predominantly 
residing in major cities.  
There were no missing choice data. Approximately half of the sample completed each survey 
version (version 1 16/35 or 46%; version 2 19/35 or 54%). No respondents opted for the 
alternative ‘no screening’, indicating that early detection of melanoma was of high relevance to all 
participants. The ‘no screening’ option was therefore removed from the models. The skin self-
assessment alternative was chosen on 36 separate occasions (choice sets) by 6 different 
participants. This is a small proportion (36/420; 8.6%) of the total possible 420 choice sets 
across all 35 participants, suggesting a strong preference in this cohort to take up a form of 
screening that involves a medical doctor. 
Results from the MMNL model are presented in Table 4.  
 
<< Table 4 about here >> 
Participants strongly preferred their screening results to be reviewed by a dermatologist rather 
than a GP; a high chance (>95%) of detection during screening; that less non-cancerous moles 
(3) are removed to detect one skin cancer, rather than more (10); and lower cost (all p-
values<0.05). Not spending greater than 4 hours away from usual activities was preferred, but 
this was only significant at the 10% level. No significant difference was found between the 
different screening methods in terms of their effect on screening choice (teledermoscopy 
compared to visiting a skin cancer clinic or a GP). However, teledermoscopy results were the 
only results reviewed by a dermatologist in the available choices and participants had been made 
aware of this in the survey. There was a non-linear preference observed for the levels of the 
attribute “length of time to receive results”, with a wait time of up to one day preferred to less 
than 4 hours; however, this relationship was only significant at the 10% level. Participating in a 
screening service involving a doctors’ opinion either during a face-to-face visit or by 
telediagnosis was strongly preferred over skin self-examination as shown by the negative and 
statistically significant constant for this alternative. We tested a range of additional variables to 
investigate whether they explained the variation in participant choices for screening. These 
included the participant socio-demographics shown in Table 3, whether participants had 
previously been diagnosed with skin cancer, if they had a skin cancer detected during the trial, if 
they were more worried about developing skin cancer in the future and if they currently 
performed skin self-examination. None of these variables were shown to significantly explain 
heterogeneity around choices and they were therefore excluded from the final model.  
The indicative marginal willingness-to-pay (MWTP) calculation is shown in Table 5. 
<< Table 5 about here >> 
Here, we consider an initial ‘state of the world’ as being comprised of three different screening 
options, which were chosen as being most indicative of the current options available: skin self-
examination, skin cancer clinic or GP screening. We assume a 1-2 hour distraction from usual 
activities, greater than 95% chance of detecting a skin cancer if one is present, a wait time of less 
than 4 hours for results, that the results are reviewed by a GP, and that 5 non-cancerous moles 
are removed for every skin cancer detected for services provided in a skin cancer or GP clinic. 
The introduction of a teledermoscopy alternative as an additional (fourth) screening mode, 
assumes review by a dermatologist and that only 3 non-cancerous moles need to be removed to 
detect one skin cancer. The use of a lower rate of non-cancerous mole removal by 
dermatologists has been justified by previous findings [15].  This change, from three screening 
options to four screening options is associated with an average welfare improvement of AU$110 
(estimated using the Small & Rosen compensating variation equation (Appendix 2). This is 
interpreted as consumers being willing to pay an average of $110 to move the current situation 
where they can choose between skin self-examination, skin cancer clinic and GP screening 
alternatives only, to a situation where all of these options plus teledermoscopy with 
dermatologist review being available. The likelihood of uptake of the different alternatives also 
changes (Table 5). Whilst the skin cancer clinic model is the most demanded initially (0.548 
probability of uptake), the new teledermoscopy model is the most likely to be taken up after its 
introduction (probability of uptake 0.668). This likelihood of uptake and welfare gain is driven 
primarily by having review of the results by a dermatologist rather than a GP.     
Given the strong preference for skin examination by a dermatologist, we conducted further 
hypothetical modelling assuming that dermatologists would staff skin cancer clinics and achieve a 
lower rate of mole removal (3 for every skin cancers detected). In this scenario, the welfare 
improvement associated with the teledermoscopy (fourth) option is estimated to be AU$52 
(results not presented). Thus, teledermoscopy still provides additional welfare gains to 
consumers beyond access to a dermatologist and a lower rate of mole removal.  
Discussion 
This study uses discrete choice methods to elicit consumer preferences for skin cancer screening 
services, including novel teledermoscopy screening. This new technology offers consumers the 
chance to ‘store and send’ an image of any potential skin cancer for review by a health 
professional. The findings suggest that people 50-64 years at high risk of skin cancer strongly 
preferred their results to be reviewed by a dermatologist – an option that was only available using 
teledermoscopy in the survey, and would likely only be available via teldermoscopy for the 
majority of consumers in the Australian health system, where family doctors must be consulted 
first before any specialist appointment. Results also show that a higher skin cancer detection rate 
and lower rate of removal of non-cancerous lesions are also strongly preferred, as is a shorter 
time away from usual activities. There was an unexpected non-linear preference observed for 
levels of the attribute length of time to receive results. However, this was not significant at the 
conventional 5% level. Furthermore, any such trend could indicate that people prefer a fast, but 
also thorough assessment of their skin lesions.  
Many of the results found supporting the importance of particular attributes in this study are in 
concordance with the previous literature focusing on consumer satisfaction with teledermoscopy 
or teledermatology more broadly [14, 18, 19, 27, 28]. For example, Whited et al. found that the 
majority of consumers agreed that they had confidence that dermatologists can diagnose 
teledermatology pictures and that a teledermatology consult is more convenient than going to a 
dermatologist clinic [22]. Qualitative and quantitative results from Collins et al. show no 
difference in the overall satisfaction depending on the type of consultation (face to face 
compared with teledermatology) [17] and that both groups were happy with their care. This is 
despite concerns by some consumers that they would like more personal or face-to-face 
communication. In relation to waiting time, Azfar et al. asked specifically “how many days would you 
be willing to wait to get a response from mobile teledermatology in exchange for the convenience of not having to 
travel so far or wait for a face-to-face consultation”? Interestingly, the majority (40%) of participants 
answered 1-3 days compared with 19% who wanted the answer on the same day. This is similar 
in some ways to the wait attribute results found in this study where the level “up to 1 day” was 
preferred over both “less than 4 hours” and “up to 3 days” (although, this only reached 
significance at the 10% level). It is uncertain why participants may prefer not to receive results 
straight away, but this may reflect peoples’ assumptions about how long it will take for results to 
be processed. Future research should explore this question in more detail.  
The use of a DCE methodology here is an advance on the existing literature which relied on the 
use of satisfaction rating scales, which don’t allow for the relative importance of different aspects 
of the service to be directly compared [37]. This is important when designing how 
teledermoscopy might be incorporated into the current health system as it helps to inform 
decisions about who reviews the results, in what time frame and the acceptance of any out-of-
pocket costs. The indicative welfare gain of AU$110 to have teledermoscopy available as an 
additional screening option strongly suggests this screening mode could provide a societal 
welfare gain, even after considering the comparative costs of providing this service. 
Nevertheless, given the limitations associated with the sample (discussed below), this estimate 
requires confirmation in larger representative samples before being implemented. The results 
however indicate that participants found the option of teledermoscopy valuable and would likely 
to take it up if it was available, all other things being equal. This estimate is also sensitive to the 
assumption that skin cancer clinics are staffed by GPs rather than dermatologists and the 
estimate drops to AU$52 if  this assumption is not met in practice. Given the relative shortage of 
dermatologists, we think the implementation of teledermoscopy is more feasible than skin cancer 
clinics being predominantly staffed by dermatologists, at least in the short to medium term.  
In terms of limitations, this study used a small homogenous sample of participants at moderate 
to high risk of melanoma, all with experience using teledermoscopy in a previous component of 
this study [11]. As such, the generalizability of these results are limited. Nevertheless, the 
preferences elicited in this DCE are indicative of the likely preferences of a group of consumers 
who are at moderate to high risk of skin cancer and who are therefore a population of particular 
interest for targeted screening strategies. Further, due to the particular nature of the Australian 
health service, where GP visits are publicly funded and access to a dermatologist requires a GP 
referral, results cannot inform policy makers in other countries without further confirmation. 
However, this study outlines an approach to undertaking a similar study in a larger international 
sample, which would be advisable to inform implementation of teledermoscopy on a global 
scale.    
Overall, we found that many of the aspects of skin cancer screening and skin cancer triage 
offered by teledermoscopy are valued by consumers at moderate to high risk of skin cancer, 
which is an important consideration for health service design. Teledermoscopy is an innovative 
technology which potentially offers at least equivalent health outcomes for consumers, delivered 
in a more acceptable way and may offer improved health service efficiency.  
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Table 1: Attributes and levels used in the Discrete Choice Experiment (DCE) 
Attributes (name used in 
model) 
Health service A or B +/- SSE Skin self-
examination (SSE) 
only^ 
Method of screening (type) 
 
Diagnosis using a phone camera 
(type1) 
Visit a skin cancer clinic (type2) 
Visit your GP (base)  
Checking yourself  
Time away from 
home/office/usual activities 
including travel (time) 
More than 4 hours (time1) 
3-4 hours (time2) 
1-2 hours (base) 
The time it takes to 
check your whole 
body  
Chance of detection of melanoma 
if one is present (chance) 
 
More than 95% (chance1) 
85-95% (chance2) 
65-75% (base) 
50% or less (constant) 
Wait time to get result (wait) 
 
Up to 3 days (wait1) 
Up to 1 day (wait2) 
Less than 4 hours (base) 
blank  
Who reviews the result (who) 
 
GP† (1) (who) 
Telederm dermatologist (base) 
No-one  
Number of non-cancerous moles 
removed to find one melanoma 
(benign) 
 
3 non-cancerous for one skin 
cancer (benign1) 
5 non-cancerous for one skin 
cancer  (benign2) 
10 non-cancerous for one skin 
cancer (base) 
None  
Out of pocket cost* (cost) continuous No cost 
* not including additional costs for biopsy or follow-up tests or treatment 
† constrained to be a GP who reviews the result if appearing with screening being performed at a skin cancer clinic 
or GP clinic 
^ The levels for the SSE were described in the survey text  
 
 
 
 
 
 
 
 
 
 
Table2: An example choice question 
Question 1: Which routine skin check would you prefer from the following choices? Please tick 
your choice. 
  Health Service A   Health Service B   Skin self‐
examination  
I would 
not 
perform 
a 
routine 
skin 
check  
Method of screening   Visit a skin cancer 
clinic 
Diagnosis using a phone 
camera 
 
Time away from usual 
activities  
more than 4 hours  more than 4 hours 
Chance of accurately 
diagnosing a skin 
lesion  
65‐75%  65‐75% 
Wait time to get 
result  
up to 1 day  up to 3 days 
Who reviews the 
result  
GP performing the 
service 
A dermatologist 
Number of non‐
cancerous lesions 
removed to detect 
one skin cancer  
10 removed to detect 
one skin cancer 
3 removed to detect 
one skin cancer 
Out of pocket cost   $60  0 
        
 
 
 
 
 
 
 
 
 
 Table 3: Summary of participant characteristics 
 
Variable Description Proportion Percentage 
Age 50-54 years 19/35 54 
 55-59 years 12/35 34 
 60-64 years 4/35 11 
Gender female 19/35 54 
Education university degree 19/35 54 
 post-school certificate 10/35 29 
 high school or less 6/35 17 
Employment employed full/part time 26/35 74 
Income >$60,000 28/35 80 
 <$60,000 4/35 11 
 prefer not to say 3/35 9 
Geographical location major city 30/35 86 
 regional centre 4/35 11 
 rural or remote 1/35 3 
Ever had skin cancer removed  not moles or warts 16/35 46 
Diagnosis of skin cancer in teledermoscopy trial* 5/35 14 
* All 5 skin cancers detected in the previous teledermoscopy trial were basal cell or squamous 
cell carcinomas (BCCs or SCCs). No melanomas were detected in the trial [11].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4: Result of mixed multinomial logit (MMNL) model 
   95% CI RP dist 
Attribute description MMNL   s.e. lower upper  s.d.   
teledermoscopy screening -0.046 0.129 -0.298 0.207 
skin cancer clinic screening 0.172 0.137 -0.096 0.440 
base: GP screening -0.127
time away from usual activities > 4 hours  -0.233 * 0.125 -0.478 0.011 
time away from usual activities 3-4 hours  -0.144 0.149 -0.436 0.148 
base: 1-2 hours 0.377
>95% chance of skin cancer detection  0.865 *** 0.180 0.513 1.218 0.628 ***
85-95% chance of skin cancer detection  0.202 * 0.119 -0.031 0.436 
base: 65-75% chance of skin cancer detection  -1.068
wait time to get results up to 3 days  -0.069 0.132 -0.328 0.190 
wait time to get results up to 1 day  0.258 * 0.132 -0.001 0.516 
base: wait time to get results < 4 hours -0.189
Result reviewed by GP  -0.458 *** 0.114 -0.681 -0.235 0.344 ***
base: Result reviewed by dermatologist 0.458
3 non-cancerous moles removed for 1 skin cancer 0.532 *** 0.164 0.210 0.855 0.514 ***
5 non-cancerous moles removed for 1 skin cancer -0.061 0.123 -0.303 0.180 
base: 10 non-cancerous moles removed for 1 skin cancer  -0.471
Cost (continuous) -0.010 *** 0.004 -0.017 -0.003 
Skin self-examination  -1.987 *** 0.217 -2.412 -1.562     
McFadden Pseudo R-squared      0.328       
***,**,* indicates significance at the 1%, 5% and 10% level respectively.  
Abbreviations: MMNL = mixed multinomial logit; CI = confidence interval; RP = random parameter; dist = 
distribution; s.e. = standard error; s.d.= standard deviation;  
 
 
 
 
 
 
 
 
 
 
Table 5: Willingness to Pay for teledermoscopy to be available as an additional 
alternative 
 Probability of uptake 
 SSE Skin cancer 
clinic 
GP teledermoscopy
Three available 
alternatives 
0.037 0.553 0.410 NA 
Four available 
alternatives 
0.012 0.183 0.136 0.668 
Willingness-to-pay for the situation where teledermoscopy is available 
additional to existing three options:  
$110 
 
Abbreviations: SSE = skin self-examination; GP = general practitioner  
Notes: (1) The ‘initial state of the world’ includes 3 available alternatives: SSE, skin cancer clinic 
screening & GP screening. The ‘state of world’ after policy change includes four available 
alternatives: SSE, skin cancer clinic screening, GP screening & teledermoscopy.  
(2) The estimates for probability of uptake assume differences in three attributes: (i) the type 
attribute; (i) who reviews the results; and (ii) the benign attribute. The level of the benign attribute 
for the teledermoscopy alternative is set to the ‘3 non-cancerous moles removed for 1 skin 
cancer’ level, whereas this is ‘5 non-cancerous moles’ for GP and skin cancer clinic alternatives. 
Dermatologist review is assumed for the teledermoscopy alternative, GP review is assumed for 
the skin cancer and GP clinic alternatives. The best levels for all other attributes are chosen and 
held constant across the GP, skin cancer clinic and teledermoscopy alternatives.   
(3) The Small and Rosen formula used to calculate compensating variation is shown in Appendix 
2.  
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 1: Theoretical framework for analysis 
The DCE data were analysed in a conventional random utility theoretical framework using 
regression models, in which the attribute levels (independent variables) were used to explain 
screening choice (dependent variable). The most-widely used choice model is the multinomial 
logit (MNL) model which estimates the average contribution to utility, or satisfaction, across the 
sample of each attribute level compared to its base level. The utility function may be expressed 
as: 
Equation 1:            
where U is the utility the nth consumer derives from alternative j; V is the observed 
component of utility (comprising of a linear combination of parameters (β) and attribute levels 
(xk), as specified in Equation 2), and  is the unobserved component (idiosyncratic error term). 
Equation 2:      
   
One of the limitations of the MNL model is that it imposes quite restrictive assumptions, 
including the homogeneity of preferences and independence of choices even over repeated 
choice questions, which are likely to be violated [32]. For this reason, the mixed  logit (MMNL) 
model is often preferred to the MNL as all of the restrictive assumptions of the MNL may be 
relaxed [32, 33]. In a MMNL model, one or more of the parameters in the model are treated as 
random, as represented by: 
Equation 3:  
 where  is the marginal mean utility in the sample;  is the deviation of the mean 
marginal utility for respondent n for attribute k, which is part of alternative j in choice question s; 
and represents an underlying distribution (such as normal, triangular or log-normal).  
 
 
 
 
 
 
 
 
 
Appendix 2: The Small and Rosen formula for compensating variation. 
 
 
 
 where: CV = compensating variation – a measure of how much money needs to be given 
or taken from a consumer after a price or quality change to leave them at their initial level of 
utility; γ = the marginal utility of income (approximated here by the negative coefficient of the 
cost attribute);  and  are the values of the indirect utility functions for each choice option j 
before and after the quality (attribute level) change; and J is the number of options in the choice 
set.  
 
From: Small, KA & Rosen, HS (1981). Applied welfare economics with discrete choice models. 
Econometrica; 49:105-130.  
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